Intensity Therapeutics' Data on Lead Asset, INT230-6, Accepted for Three Presentations at Key Upcoming Clinical Oncology Conferences in November

/PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity"), a clinical-stage biotechnology company focused on the discovery and development of proprietary,...

Related Keywords

Boston ,Massachusetts ,United States ,Canada ,Westport ,Newfoundland ,Vancouver ,British Columbia ,Ottawa ,Ontario ,Edna Kaplan ,Merck Sharpe Dohme ,Angel Arnaout ,Jacob Stephen Thomas ,Michael Miller ,Bristol Myers Squibb ,Matthew Ingham ,Development Agreement ,Ontario Institute Of Cancer Research ,Ottawa Hospital Research Institute ,National Cancer Institute ,Society For Immunotherapy Of Cancer ,Exhibition Center ,Bristol Myers Squibb Company ,Intensity Therapeutics Inc ,Rx Communications Group ,Vaccine Branch ,Boston Convention ,Connective Tissue Oncology Society ,Vancouver Convention Center ,York Presbyterian Hospital Columbia University Medical Center ,Division Of Hematology ,Two Poster Presentations Will Be Made ,Metastatic Sarcomas Selected ,Oral Podium Presentation ,Intensity Therapeutics ,Annual Meeting ,Opportunity Trial Evaluating Cytotoxic ,Early Stage Breast Cancer ,Survival Results From ,Intratumoral Agent ,Induces Immunological Cancer Cell Death Alone ,With Pembrolizumab ,Assistant Professor ,New York Presbyterian ,Columbia University Medical ,Ipilimumab Prolonged Survival ,Favorable Safety ,Refractory Sarcomas ,Date Friday ,Merck Sharpe ,Ontario Institute ,Cancer Research ,Cooperative Research ,Relations Contact ,Nc ,